Published Paper Details:

This research focuses on creating and validating a HPLC method to concurrently measure Tamsulosin HCL and Fexofenadine in pharmaceutical products. The method development involved optimizing chromatographic conditions using a Symmetry C18 column and a mobile phase composed of Buffer, Methanol, and Acetonitrile (BMA, 50:10:40, pH 5 adjusted with OPA). These conditions resulted in well-defined peaks with satisfactory separation and symmetry for both substances. Validation of the method included assessing linearity over a concentration range of 4+1800 to 12+5400?g/ml for each compound, demonstrating strong correlation coefficients (R^2 > 0.999). Specificity testing confirmed that there were no interferences from excipients, ensuring precise quantification of the drugs. Accuracy studies showed recovery rates between 95-103%, indicating the method's reliability in determining drug concentrations. Precision studies revealed low %RSD values (<2%) for both intra-day and inter-day variability, indicating excellent repeatability and reproducibility. The method's sensitivity was assessed with LODs of 0.36?g/ml for Tamsulosin HCL and 163.75?g/ml for Fexofenadine, and LOQs of 1.08?g/ml and 496.20?g/ml, respectively. The developed RP-HPLC method was successfully applied to analyze a synthetic mixture containing Tamsulosin HCL and Fexofenadine, confirming its suitability for routine quality control analysis in pharmaceutical formulations. Overall, this method provides a reliable approach for accurate and precise quantification of Tamsulosin HCL and Fexofenadine in complex matrices.